Valneva SE Sponsored ADR (NASDAQ:VALN) Receives $9.30 Consensus Target Price from Brokerages

Valneva SE Sponsored ADR (NASDAQ:VALN) has been given a consensus rating of “Hold” by the four research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and two have given a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $9.30.

Several equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. TD Cowen started coverage on Valneva in a research note on Tuesday, August 11th. They issued a “buy” rating and a $12.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research report on Thursday, June 18th.

Valneva Stock Down 2.0%

NASDAQ:VALN opened at $6.30 on Tuesday. The company has a debt-to-equity ratio of 2.04, a current ratio of 2.16 and a quick ratio of 1.69. The firm’s 50-day moving average price is $5.55 and its 200-day moving average price is $6.70. The company has a market capitalization of $597.81 million, a PE ratio of -2.99 and a beta of 1.77. Valneva has a 1-year low of $4.75 and a 1-year high of $12.23.

Valneva (NASDAQ:VALN) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The business had revenue of $39.37 million for the quarter, compared to analysts’ expectations of $44.17 million. On average, equities analysts predict that Valneva will post -1.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Valneva

Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new position in Valneva in the 3rd quarter worth about $124,000. XTX Topco Ltd bought a new stake in Valneva during the 4th quarter valued at about $94,000. Marex Group plc bought a new stake in Valneva during the 2nd quarter valued at about $64,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Valneva in the fourth quarter worth about $44,000. 11.39% of the stock is currently owned by institutional investors.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.